Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorGuangdong Hengrui Pharmaceutical Co., Ltd

About this trial

To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy

Age 18-75 years, regardless of gender;

Weight ≥40.0 kg at screening;

Diagnosed as primary membranous nephropathy through kidney biopsy.

Secondary membranous nephropathy.

Subjects developed rapidly progressive glomerulonephritis or required kidney transplantation.

Subjects who have undergone kidney dialysis in the previous 12 months or are expected to require dialysis during the study period.

Subjects who have a malignant tumor or a history of malignant tumor

75 Participants

are divided into 3 treatment groups

Guangdong Hengrui Pharmaceutical Co., Ltd

Lead sponsor